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Abstract. Age-related bone loss eventually leads to osteo-
penia in men and women. The etiology of age-related bone
loss is currently unknown; however, decreased osteoblast
activity contributes to this phenomenon. In turn, osteoblast
proliferation and function is dependent on energy produc-
tion, thus the loss of energy production that occurs with age
may account for the deficient osteoblast activity. Carnitine
and dehydroepiandrosterone-sulfate (DHEAS), both of
which decline with age, promote energy production through
fatty acid metabolism. Thus, we hypothesized that carnitine
and DHEAS would increase osteoblast activityin vitro. Ac-
cordingly, we measured the effect of carnitine and DHEAS
on palmitic acid oxidation as a measure of energy produc-
tion, and alkaline phosphatase (ALP) activity and collagen
type I (COL) as indices of osteoblast function in primary
porcine osteoblast-like cell cultures. Carnitine (10−3 and
10−1 M) but not DHEAS (10−9, 10−8, and 10−7 M) increased
carnitine levels within the cells. Carnitine alone and in com-
bination with DHEAS increased palmitic acid oxidation.
Both carnitine and DHEAS alone and in an additive fashion
increased ALP activity and COL levels. These results dem-
onstrate that in osteoblast-like cellsin vitro, energy produc-
tion can be increased by carnitine and osteoblast protein
production can be increased by both carnitine and DHEAS.
These data suggest that carnitine and DHEAS supplemen-
tation in the elderly may stimulate osteoblast activity and
decrease age-related bone loss.
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Bone loss is often divided into two broad mechanisms: (1)
postmenopausal bone loss, characterized by increased os-
teoclast activity, and (2) age-related bone loss, characterized
by decreased osteoblast activity. Osteoblast activity is de-
pendent on energy production. Thus, it is plausible that the
loss of energy production, which accompanies age, may
account for decreased osteoblast activity. Most cells use
both glucose and fatty acid oxidation pathways for ATP
synthesis, although some cell types show a substrate pref-
erence. For instance, some studies have suggested that glu-
cose is the major fuel substrate for bone [1, 2]. However,
more recent work indicates that cell populations enriched
with osteoblast-like cells generate 40–80% of the energy
demands through fatty acid oxidation [3]. Osteoblasts are
responsible for bone formation and it follows that they
maintain a high rate of ATP utilization to support the req-
uisite protein synthesis. Cells with a high rate of protein
synthesis generate ATP from fatty acid oxidation, the most
efficient metabolic process for energy production [4–6].
Thus, modulation of fatty acid oxidation may regulate the
amount of energy available for protein synthesis in osteo-
blasts.
A number of factors are required for fatty acid oxidation.
For example, carnitine is the requisite carrier for the trans-
port of long-chain fatty acids across the inner mitochondrial
membrane into the mitochondrial matrix [7]. In muscle,
carnitine concentration decreases with advancing age
[8–10]. This decline may contribute to diminution of mito-
chondrial function associated with age. We have observed
that the ratio of esterified to free carnitine in the peripheral
blood increases with age [11], suggesting a declining ability
for fatty acid transport. Accordingly, this decline may con-
tribute to reduced energy availability with age, culminating
in cardiomyopathy, hepatic encephalopathy, or skeletal
muscle weakness [12]. This loss of energy availability could
also compromise osteoblast activity and bone production in
an age-related manner.
Another factor indirectly related to fatty acid oxidation is
dehydroepiandrosterone (DHEA), an intermediate in the
pathway for the synthesis of testosterone, estrone, and es-
tradiol [13]. DHEA and its sulfated derivative, DHEAS, are
interconvertible and DHEAS is the major source of circu-
lating DHEA [14]. The physiologic roles of DHEA and
DHEAS have not been conclusively defined. However,
DHEA and DHEAS increase lipid metabolism and mito-
chondrial respiration [15, 16]. This may be accomplished
through DHEA’s ability to increase the synthesis and activ-
ity of carnitine acyltransferases, enzymes which catalyze the
reversible transfer of the fatty acid moiety from fatty acyl
CoA to fatty acyl-carnitine [17, 18]. Additionally, our labo-
ratory has demonstrated that DHEAS administration in-
creases hepatic and cardiac carnitine levels and carnitine
acetyl transferase activities in young adult oophorectomized
rats [19]. Taken together, these observations stimulate ques-Correspondence to:S. Gravenstein
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tions about potential roles that DHEA, through promotion
of energy metabolism, might play on osteoblast activity.
As osteoblasts have high-energy requirements and both
carnitine and DHEAS play an important role in energy me-
tabolism we propose that both carnitine and DHEAS pro-
mote fatty acid oxidation and energy metabolism in osteo-
blasts. Accordingly, the aim of this study was to investigate
the effects of carnitine and DHEAS on primary cultures of
porcine bone marrow stromal cells (BMSC).
Materials and Methods
Cell Isolation and Culture
Porcine bone marrow stromal cells were isolated using the meth-
ods described by Thomson et al. [20]. Briefly, cultures consisting
of bone marrow stromal cells (progenitor osteoblast cells) and
trabecular bone cells (mature osteoblast cells) were prepared from
distal femurs of young, 3 to 4-week-old pigs. Soft tissue was
removed, the bone was immersed in 70% ethanol, and then trans-
ferred to a flow hood for aseptic collection of bone cells. Bones
were sectioned at the metaphysis, and tissue from trabeculae and
medullary cavity as transferred into a flask containing Dulbecco’s
Modified Eagle’s Medium (DMEM) (Gibco, Grand Island, NY)
plus 10% fetal bovine serum (FBS) (Biowhittaker, Inc. Walkers-
ville, MD). Cells were grown to confluence, then nonadherent cells
were discarded and adherent cells were subcultured to a new flask
following treatment with trypsin-EDTA (0.05% trypsin, 0.53 mM
EDTA-4Na) (Gibco, Grand Island, NY). Medium was completely
changed twice weekly and adherent bone marrow stromal cells
were passed approximately weekly when cultures became conflu-
ent. These cell cultures were heterogeneous and included osteo-
blast-like cells at various stages of differentiation [20].
Mineralized Bone Nodule Formation
Cultures were grown with 50mg/ml ascorbic acid, 10 mMb-glyc-
erophosphate, and 10−8 M dexamethasone for 7–10 days, as pre-
viously described by Maniatopoulos et al. [20]. Under these con-
ditions, mineralized bone nodules were identified by staining the
cell cultures with Alizarin red S.
Histochemical Staining for Alkaline Phosphatase
Bone marrow stromal cells were seeded at 2 × 105 cells in a 35 mm
culture dish with 10% FBS/DMEM, and cultured for 24 hours. The
medium was then removed and BMSC were fixed in 10% neutral
buffered formalin. Alkaline phosphatase was stained using Im-
munoPure Fast Red TR, (Sigma Chemical Co., St. Louis, MO) the
naphthol phosphate AS-MX.
Determination of Cell Number and Viability
DNA Incorporation.Cells were seeded in 96-well plates (4000
cells/well) in 0.1% FBS/DMEM for 24 hours to synchronize the
cell cycle. DMEM with 10% FBS and [3H]thymidine (0.2mCi/ml)
(New England Nuclear, Boston, MA) were added and the cultures
were incubated for 20 hours at 37°C. At the end of this 20-hour
incubation period, the medium was removed and cell layers were
washed three times with PBS. Cells were then trypsinized for 20
minutes and harvested onto fiberglass filter papers, and the radio-
activity was counted with ab-scintillation counter (1600TR,
Parkard, Meriden, CT).
Cell Viability
Trypan blue exclusion.Cells were plated in 35 mm culture
dishes at an initial density of 2 × 105 cells/dish in 0.1% FBS/
DMEM. After a 24-hour attachment period, the medium was
changed to 10% FBS/DMEM for another 24-hour incubation at
37°C. The cells were then released by trypsin, a 0.04% (w/v)
trypan blue solution in phosphate-buffered saline (PBS) was
added, and the number of viable cells (nonstained) were counted
using a hemacytometer.
MTT [3, (4, 5-Dimethylthiazol-2-yl) 2, 5-diphenyl-tetrazolium
Bromide] Assay.MTT assay is an indirect measurement of cell
growth. Cells were cultured in 96-well plates (4000 cells/well) in
0.1% FBS/DMEM for 24 hours. DMEM supplemented with 10%
FBS was added and the cultures were incubated for another 24
hours at 37°C. MTT [3, (4, 5-dimethylthiazol-2-yl) 2, 5-diphenyl-
tetrazolium bromide] (Sigma) was added and after 4 hours of
incubation, cells were extracted with an extraction buffer (N, N-
dimethyl formamide/sodium dodecyl sulfate) to lyse the cells and
solublize all formazan dye grains [22]. After an overnight incuba-
tion, optical densities at 570 nm were measured by automated
ELISA plate reader (Dynatech MR650, Alexandria, VA).
Addition of Treatments
The cells were cultured in 2% FBS/DMEM in 96-flat-bottom-well
plates (4000 cells/well). After an attachment period of 24 hours,
either or both carnitine and DHEAS were added at the indicated
concentrations and the cells were cultured for an additional 72
hours. L-carnitine (Austin Chemical Co., Chicago, IL) was dis-
solved in 2% FBS/DMEM to provide final concentrations in cul-
ture media of 10−1 M, 10−2 M, and 10−3 M. DHEAS (Sigma)
was dissolved in 100% ethanol to provide a 10−3 M stock solution,
and then diluted into 10−7 M, 10−8 M, and 10−9 M final concen-
trations with 2% FBS/DMEM. Carnitine and DHEAS were added
to the cell culture separately or in the following combinations: 10−1
M carnitine plus 10−7 M DHEAS, 10−1 M carnitine plus 10−8 M
DHEAS, or 10−1 M carnitine plus 10−9 M DHEAS. For the control,
only 2% FBS/DMEM was added to the cell culture.
Alkaline Phosphatase Assay (ALP)
At the end of the 72 hour incubation period, the medium was
removed. The cells were then rinsed with PBS and lysed by three
freeze-thaw cycles in lysate buffer (0.1% Triton X-100, 10 mM
Tris, and 0.5 mM MgCl2). ALP activity was measured at 37°C
following the addition of 2 mg/ml ofp-nitrophenylphosphate
(Sigma) substrate [19]. The plates were read at 410 nm using a
plate reader (Dynatech MR650). Bovine intestinal mucosal ALP
(Sigma) was used to construct a standard curve. One unit of en-
zyme activity equals onemmole product formed per minute.
Collagen Type I Assay (COL)
The COL concentration was measured by ELISA [23] and modi-
fied from the immunocytochemistry method from Thomson et al.
[20]. At the end of the 72-hour incubation period, the medium was
removed. The cells were then rinsed with PBS and fixed with 4%
formalin for 10 minutes at room temperature. The cells were then
rinsed with PBS-T twice. Goat anti-type I collagen antibody (0.4
mg/100 ml/well) (Southern Biotechnology Associates, Inc., Bir-
mingham, AL) was added and incubated for 2 hours at room
temperature, then rinsed with PBS-T three times. Anti-goat IgG
conjugated with ALP (0.135mg/150ml/well) (Sigma) was used as
a second antibody and incubated for another 2 hours at room
temperature. The cells were then rinsed with PBS-T three times.
p-Nitrophenylphosphate (1 mg/ml) was added and the absorbance
at 410 nm was recorded as described above. Interference from
endogenous cellular ALP activity, determined by using the ALP-
conjugated secondary antibody alone, was minimal.
Carnitine Assay
Incubation was terminated, the medium was decanted, and the cell
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layers were rapidly rinsed three times with cold PBS. The cells
were lysed by three freeze-thaw cycles in lysate buffer (0.1%
Triton X-100, 10 mM Tris and 0.5 mM MgCl2). The cell lysates
were stored at −80°C until analysis. Carnitine was measured in
triplicate by quantitative radioenzymatic assay slightly modified
from that reported by Parvin and Pande [24]. Free carnitine was
measured in untreated samples whereas total carnitine was deter-
mined after alkaline hydrolysis. Results were expressed as nmol/
mg noncollagen protein (NCP). NCP was determined by Biorad
micro protein assay kit with globulin as a standard (#500–0001
protein assay kit, Bio-Rad Laboratories, Inc., Hercules, CA) [25].
Fatty Acid Oxidation
The cells were seeded in 35 mm culture dishes (2 × 105/dish) in
2% FBS/DMEM. After an attachment period of 24 hours, carnitine
and DHEAS were added separately or in combination to the cul-
tures. [9,10−3 H]-Palmitic acid (0.5mCi/ml, specific activity 56.5
Ci/mmol) (Du Pont-New England Nuclear, Wilmington, DE) and
nonradioactive palmitate were prebound to fatty acid free albumin
(Sigma) and added to provide a final concentration of 0.4 mM
palmitate. After 24-hours of incubation at 37°C, the medium and
cell lysate were used to measure the tritiated water production as
an estimate of exogenous fatty acid oxidation. Tritiated water,
formed duringb-oxidation of labeled [9,10−3 H]-palmitic acid,
served as a tracer for exogenous fatty acid transport and oxidation.
The medium or cell lysate was added to 5 ml of Dole-Meinertz
extraction solution [26], vortexed, and then allowed to stand for 15
minutes. After adding 2 ml of water and 3 ml of heptane and
vortexing, it was allowed to stand for 15 minutes and then the
upper organic phase was removed. The lower aqueous phase,
which contained3H2O and acid-soluble products of fatty acid me-
tabolism, was then counted on a Parkad Tricarb liquid scintillation
counter.
Statistical Analysis
For total and free carnitine concentrations and palmitate oxidation,
analysis of variance (ANOVA) was used to compare the means of
control and treated groups. Data were expressed as the mean ±
standard error of the mean (SEM). For ALP activities and COL
levels, ANOVA on rank-transformed data for randomized com-
plete block design was performed to compare the different groups
[26]. Data were expressed as median (first quartile-third quartile).
Data analyses were conducted using SAS (SAS Institute Inc.,
Cary, NC) and Statview version 4.02 Software (Abacus Concepts,
Berkeley, CA). Significant difference was set atP ø 0.05.
Results
Model System
This model system has been previously well described [20].
However, mineralizing capability and the ALP activity were
measured to confirm the presence of osteoblast-like cells in
our cultures. Mineralized bone nodules were formed in the
primary cultures indicating that osteoblast-like cells were
present (Fig. 1). Immunochemical ALP-positive staining
also supported the presence of osteoblast-like cells in the
cultures (data not shown). The three assays (3H thymidine,
trypan blue exclusion, and MTT) used to assess DNA in-
corporation and viability of the bone marrow stromal cells
Fig. 1. Cells harvested from the porcine distal femur are capable
of mineralization. Cells were harvested from the distal femoral
metaphyseal trabeculae of pigs. They were then grown with 50
mg/ml ascorbic acid, 10 mMb-glycerophosphate and 10−8 M
dexamethasone in 10% FBS/BGJb medium for 7–10 days at which
time they were then stained with Alzarin red.
Fig. 2. Osteoblast-like cell proliferation decreases with increasing
number of passages in culture. Cells were maintained in 10%
FBS/DMEM for 1st, 3rd, 5th, and 7th passages. At each passage,
cells were treated as described in Materials and Methods. Each
value (mean ± SEM) represents the average of five trials. *P ø
0.002 compared with the 3rd passage by ANOVA.
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in cultures showed similar responses across the number of
passages. The maximal DNA incorporation and cell viabil-
ity occurred in the third passage (34 ± 1.3 days old) and
gradually declined through the seventh passage (Fig. 2).
There was a 40–50% decline in both of these measures from
the third passage to the seventh passage (P 4 0.002).
Cellular Total and Free Carnitine Concentrations
Total and free intracellular carnitine levels were measured
to confirm thatin vitro administration of carnitine was ef-
fective. The total and free carnitine concentrations in the
third passage of BMSC, cultured with 10−1 M carnitine
alone or in the presence of DHEAS, increased above control
cultures approximately 90–100-fold whereas cells from cul-
tures treated with 10−2 M or 10−3 M carnitine had a 20-fold
or 3-fold increase in cellular carnitine concentrations, re-
spectively (Table 1). DHEAS did not effect the total of free
carnitine levels.
Fatty Acid Oxidation
To determine if carnitine and DHEAS, either alone or in
combination, promotes energy production, fatty acid oxida-
tion was measured using palmitate as the substrate. The
amount of palmitate oxidized by the cell cultures with 10−1
M carnitine alone or combined with DHEAS (P ø 0.01),
was greater than oxidation by control cultures (Table 2).
The combination of carnitine and DHEAS was additive.
Palmitate oxidation (P ø 0.088) tended to increase in cul-
tures treated with 10−2 M carnitine or 10−8 M and 10−7 M
DHEAS.
Osteoblast Proteins
To determine if carnitine and DHEAS-mediated energy
availability was associated with increased osteoblast protein
production, we measured ALP and COL accumulation in
culture. Both carnitine and DHEAS alone significantly in-
creased ALP activity (Table 3). Compared with the control
cultures, ALP activities increased in cultures treated with
10−2 M–10−1 M carnitine (P < 0.01). DHEAS (10−7 M–10−9
M) also stimulated ALP activities (P ø 0.05), but the re-
sponse was not dose dependent. Treatments with both car-
nitine and DHEAS were additive in increasing ALP activi-
ties when compared with the control cultures (P ø 0.01).
Over a twofold increase in COL concentration was ob-
served in cultures treated with 10−1 M carnitine and a sig-
nificant increase in cultures treated with 10−2 M carnitine
compared with the control (P ø 0.01) (Table 3). Compared
with controls, the combination of 10−1 M carnitine and
DHEAS (10−7 M–10−9 M) also increased the COL levels (P
ø 0.01). DHEAS (10−7–10−9 M) did not increase COL lev-
els significantly. Carnitine and DHEAS treatment did not
increase viable cell counts compared with control groups
(data not shown). Thus, the observed differences in ALP
and COL were not due to increased cell proliferation be-
tween the various treatments, but more likely to increased
expression of ALP and COL per a cell.
Discussion
In this study, carnitine promoted energy production through
increased fatty acid oxidation in cell cultures containing
osteoblast-like cells. Furthermore, ALP activity and COL
levels, proteins indicative of osteoblastic activity, increased
concomitant with the increased energy availability in car-
nitine-treated cells.
Lower mitochondrial carnitine concentrations are asso-
ciated with diminished activity of enzymes involved in fatty
acid oxidation [9, 28, 29]. In addition, the rate of fatty acid
oxidation and the removal of potentially toxic intracellular
acyl CoA esters are dependent upon carnitine [28, 30, 31].
We observed that carnitine treatment elevated the total car-
nitine concentration that was associated with greater fatty
acid oxidation. These findings support the fact that carnitine
supplementation increases osteoblast-like cell activity by
increasing transfer of fatty acids into mitochondria for oxi-
dation.
With advancing age, carnitine and acetyl carnitine levels
are markedly reduced in certain tissues, including muscle
[8–10]. The potential for carnitine deficiency/insufficiency
appears to increase with age, and is more prevalent among
women [11]. If there is a severe deficiency, cardiomyopa-
thy, hepatic encephalopathy, or skeletal muscle weakness
could ensue. This metabolic defect might also affect bone
formation since osteoblast activity and bone mineral density
(BMD) decline with advancing age [32, 33]. In elderly
people, if osteoblasts are carnitine deficient, less energy
may be available at the cellular level and thus limit osteo-
blast function. Cellular energy deficits caused by a decline
in mitochondrial function can impair normal cellular activi-
ties and affect the cell’s ability to adapt to various physi-
ological stresses [34].
In our study, high concentrations of carnitine are added
to stimulate palmitate oxidation, ALP activities, and COL
levels in the osteoblast-like cell cultures. Physiologic serum
Table 1. Effect of carnitine and DHEAS on total and free carnitine concentrations in pig osteoblast-like cells
Parameter Control
L-carnitine (M) DHEAS (M) L-carnitine (10−1 M) + DHEAS (M)
10−3 10−2 10−1 10−9 10−8 10−7 10−9 10−8 10−7
Total
carnitinea 2.1 ± 0.4b 6.4 ± 1.4* 43 ± 10** 225 ± 71** 2.1 ± 0.6 2.0 ± 0.5 1.9 ± 0.2 218 ± 35** 196 ± 60** 185 ± 43**
Free
carnitinea 1.7 ± 0.5 4.9 ± 1.0* 39 ± 11** 211 ± 75** 1.9 ± 0.5 2.0 ± 0.6 1.9 ± 0.3 201 ± 37** 200 ± 49** 184 ± 51**
a nmole/mg noncollagen protein, replicates
b All data are expressed as mean ± SEM. Each value represents the average of 7 replicates
* P ø 0.05; **P ø 0.01
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total carnitine levels in men and women are 55 ± 12 and 47
± 11 mmoles/liter, respectively [36]. Tissue total carnitine
levels (skeletal muscle, heart, and liver) are 14 ± 3, 9 ± 2,
and 10 ± 3 nmol/mg noncollagen protein, respectively [36].
However, high doses of carnitine therapy, from 100 up to
600 mg/kg daily, are required to treat carnitine deficiency
[35, 36]. Our demonstration that high levels of carnitine
were required to observe a significant effect on energy me-
tabolism protein production in osteoblasts agrees with these
studies. One possible explanation for the requirement of
high carnitine levels in our model is that thein vitro envi-
ronment results in inefficient utilization of carnitine as op-
posed to thein vivo environment. Further studies are re-
quired to explore this issue.
The exact physiologic role that DHEAS plays in bone
metabolism is unclear. However, several reports suggest
that DHEAS promotes bone density. For example, DHEAS
levels were correlated with skeletal maturation [37]. Addi-
tionally, DHEAS is positively correlated to BMD and de-
clines with age [38–41]. Finally, exogenous administration
of DHEA reduced cancellous bone osteopenia in oophorec-
tomized rats [42]. The mechanism through which DHEAS
mediates its effects on bone is currently unknown, but could
include direct or indirect modulation of hormonal mecha-
nisms [43]. Our data suggest that DHEAS promotes osteo-
blast activity which was not due to increased cellular car-
nitine concentration, increased energy metabolism, or dif-
ferences in cell viability. Our observation that DHEAS
increases liver total and free carnitine concentrations in rats
[19] suggests that it may also do so in bone, which would
lead to energy production. However, we could not docu-
ment that DHEAS induced either carnitine levels or fatty
acid metabolism in the osteoblast cultures. Thus, our find-
ings suggest that DHEAS promotes protein production in
osteoblasts through other mechanisms, such as increasing
mitochondrial respiration [16, 44], protein synthesis [18,
45], and enzyme activities [17, 18, 46, 47].
A limitation of our study is the use of ani vitro model
that contains a heterogenous population of cells. However,
this well-documented system has been previously used for
evaluation of osteoblast-like cells [20]. Furthermore, we
confirmed the presence of osteoblast-like cells in the cul-
tures through the identification of mineralized bone nodule
formation and ALP staining cells.
In conclusion, carnitine alone and in combination with
DHEAS stimulated the metabolic activity of early passage
osteoblast-like cellsin vitro. Carnitine achieved this through
promotion of fatty acid metabolism culminating in in-
creased osteoblast protein production. Furthermore,
DHEAS increased osteoblast protein production by an un-
defined mechanism. These findings suggest that carnitine
and DHEAS may promote osteoblast function. Thus, be-
cause carnitine and DHEAS levels decline with advancing
age, carnitine and DHEAS supplementation for promotion
of osteoblast activity and bone formation in elderly persons
may be worth investigating.
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